BH3.F PTC Therapeutics Inc.
- Market cap
- EUR 4.85B
- P/E
- -
- P/B
- 1,802.02x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BH3.F undervalued?
Graham numberThe Graham number of PTC Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PTC Therapeutics Inc. fundamental analysis
No fundamental analysis for PTC Therapeutics Inc. yet.
PTC Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PTC Therapeutics Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and…
Full company profilePTC Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PTC Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 539M | 699M | 938M | 807M | 1.73B | 1.32B |
| Gross Profit | 506M | 654M | 872M | 749M | 1.68B | 1.23B |
| Operating Income | -375M | -440M | -349M | -147M | 857M | 293M |
| EBITDA | - | -368M | -330M | -120M | 888M | 327M |
| Net Income | -524M | -559M | -627M | -363M | 683M | 38.7M |
| EPS | -7.40 | -7.65 | -8.28 | -4.68 | 8.38 | 0.46 |
| Balance Sheet | ||||||
| Total Assets | 1.94B | 1.71B | 1.90B | 1.71B | 2.90B | 3.21B |
| Total Liabilities | 1.94B | 2.05B | 2.71B | 2.80B | 3.10B | 3.40B |
| Shareholders' Equity | 1.44M | -347M | -819M | -1.10B | -205M | -191M |
| Cash & Short-term Investments | 190M | 280M | 594M | 780M | 985M | 509M |
| Cash Flow | ||||||
| Operating Cash Flow | -251M | -357M | -158M | -108M | 711M | 59.7M |
| Capital Expenditure | 85.3M | 152M | 121M | 74.2M | 300M | 19.4M |
| Free Cash Flow | -337M | -509M | -279M | -182M | 411M | 40.3M |
| Ratios | ||||||
| ROE | -36,432.6% | - | - | - | - | - |
| ROA | -27.0% | -32.8% | -33.1% | -21.3% | 23.5% | 1.2% |
| Net Profit Margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% | 2.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PTC Therapeutics Inc. dividends
PTC Therapeutics Inc. has not paid dividends in the last 5 fiscal years.
Who owns PTC Therapeutics Inc.
- Insiders 7.30%
- Institutions 92.70%
- Public & others 0.00%
- Shares outstanding 83.5M
- Free float 73.8M
PTC Therapeutics Inc. company profile
- Company name
- PTC Therapeutics Inc.
- Ticker
- BH3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 991
- Fiscal year end
- December
- Address
- 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059
- Phone
- 908 222 7000
- Website
- ptcbio.com
About PTC Therapeutics Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
PTC Therapeutics Inc. management
10- Dr. Matthew B. Klein F.A.C.S., M.D., M.S.CEO & Director · born 1972
- Dr. Allan Steven Jacobson Ph.D.Co-Founder & Independent Director · born 1946
- Mr. Pierre Gravier M.S.Chief Financial Officer · born 1985
- Dr. Neil Almstead Ph.D.Chief Technical Operations Officer · born 1967
- Mr. Eric PauwelsChief Business Officer · born 1962
- Dr. Lee Scott Golden M.D., Ph.D.Executive VP & Chief Medical Officer · born 1968
- Ms. Christine Utter CPASenior VP, Chief Accounting Officer & Head of People Services · born 1979
- Ms. Linda Montella CarterSenior VP & Chief Information Officer
- Ms. Ellen CavaleriHead of Investor Relations
- Mr. Mark Elliott Boulding J.D.Executive VP & Chief Legal Officer · born 1961